First author | Country | n | Gender (F/M) | Sample age a | Working seniority a | Type of study | TB incidence 2012 b | Screening year | TB real incidence c | PPD dose | Type of PPD d | BCG vaccination(%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Zwerling et al., 2012 [45] | Canada | 388 | 288/100 | 34,4 (26,9-44,7) y M(range) | 5 (2–12) y M(range) | Cross-sectional | 4,5 | 2007-2011 | 4,8 | 5 U | PPD-S | 36 |
Khoury et al., 2011 [40] | Minnesota, USA | 611 | Missing data | / | Start of work 100% | Cross-sectional | 3,9 | 2005-2006 | 5,3 | 5 U | PPD-S (as in national guidelines) | 82 |
Fox et al., 2009 [30] | Israel | 100 | 69/31 | 31 ± 10 y m + SD | TST-: 3,7 ± 6,1 y TST+: 8,7 ± 10,1 y QFT-: 4,6 ± 7,3 y QFT+: 4,2 ± 5,8 y m + SD | Prospective | 5,8 | 2007 | 6,1 | 5 U | PPD-S | 37 |
Vinton et al., 2009 [29] | Australia | 481 | 431/50 | 42 (20–66) y M(range) | / | Cross-sectional | 6 | 2008 | 6,1 | 10 U | PPD-S | 78 |
Larcher et al., 2012 [46] | Italy | 549 | 397/152 | 38,3 (19–64) y m(range) | / | Cross-sectional | 2,8 | 2006-2007 | 6,7 | 5 U | PPD-S (as in national guidelines) | 38 |
Nienhaus et al., 2008e [25] | Germany | 261 | 212/49 | 40 ± 10,4 y m ± SD | / | Cross-sectional | 4,5 | 2006 | 6,8 | 2 U | PPD-RT23 | 38 |
Soborg et al., 2007e [23] | Denmark | 139 | 115/24 | <30 y 17% 30–39 y 30% 40–49 y 33% ≥ 50 y 20% | / | Cross-sectional | 6,5 | 2007 | 6,9 | 2 U | PPD-RT23 | 76 |
Girardi et al., 2009 [31] | Italy | 115 | 67/48 | ≤41 y 51% >41 y 49% | / | Cross-sectional | 2,8 | 2004-2005 | 7,5 | 5 U | PPD-S | 37 |
Freeman et al., 2012e [47] | New Zealand | 325 | 270/55 | 18-30 y 49,2% 31–50 y 41,8% 51–60 y 8,9% | / | Cross-sectional | 7,6 | 2007-2008 | 8,5 | 5 U | PPD-S (as in national guidelines) | 67 |
Tripodi et al., 2009 [32] | France | 148 | 109/39 | 20-29 y 28,4% 30–39 y 19.6% 40–49 y 27,7% 50–60 y 24,3% | ≤10 y 52,7% > 10 y 47,3% | Cross-sectional | 4,3 | 2006-2007 | 9,2 | 2U | PPD-S (Tubertest) | 100 |
Alvarez-Leon et al., 2009 [33] | Spain | 134 | 101/33 | 33,4 ± 9,4 y m ± SD | 10,8 ± 8,2 y m ± SD | Cross-sectional | 15 | 2007 | 18 | 2 U | PPD-RT23 | 35 |
Casas et al., 2009 [34] | Spain | 147 | 113/34 | 43,3 (22–63) y M(range) | 18,4 (1–43) y m(range) | Cross-sectional | 15 | 2004-2005 | 19 | 2 U | PPD-RT23 | 16 |
Talebi-Taher et al., 2011 [41] | Iran | 200 | 127/73 | 34,36 ± 8,26 y m + SD | 1-10 y 69,5% 11–20 y 23% 21–30 y 7,5% | Cross-sectional | 21 | 2009-2010 | 19,5 | 5 U | PPD SACHIN (Surat) India | 100 |
Hotta et al., 2007e [24] | Japan | 207 | 132/75 | 20 (18–42) y M(range) | / | Cross-sectional | 19 | 2006 | 24 | 3 U | PPD (equivalent to PPD-S) | 93 |
Topic et al., 2009 [35] | Croatia | 54 | 51/3 | 44 (21–63) y m(range) | / | Cross-sectional | 17 | 2007 | 25 | 2 U | PPD-RT23 | 100 |
Ozdemir et al., 2010e [38] | Turkey | 76 | 33/43 | 30,4 ± 5,4 y m + SD | 3,9 ± 4,7 y m ± SD | Cross-sectional | 24 | 2005 | 31 | 5 U | PPD-S | 91 |
Torres Costa et al., 2011 [42] | Portugal | 2884 | 2068/816 | <25 y 10,4% 25–29 y 28,5% 30–39 y 27,4% 40–49 y 18,5% ≥50 y 15,2% | start of work 13,9% <1 y 4,9% 1–5 y 27,3% >5-10 y 16,1% 10–20 y 19,9% ≥20 y 18% | Cohort | 24 | 2007 | 33 | 2 U | PPD-RT23 | 100 |
Rafiza et al., 2011 [43] | Malaysia | 953 | 839/114 | <24 y 30,7% 25–29 y 35,2% 30–34 y 15,6% > 35 y 18,5% | <1 y 14% 1–5 y 47% 6–10 y 17,5% ≥ 11 y 21,5% | Cross-sectional | 81 | 2008-2009 | 83 | 2 U | PPD-RT23 | 100 |
Choi et al., 2008 [26] | South Korea | 80 | 75/5 | 28 (23–45) y M(range) | 26 (12–240) m M(range) | Cross-sectional | 100 | 2006 | 90 | 2 U | PPD-RT23 | 100 |
Lee et al., 2009 [36] | South Korea | 196 | 196/0 | 23,4 ± 1,4 y m + SD | / | Prospective | 100 | 2007 | 92 | 2 U | PPD-RT23 | 93 |
Lee et al., 2010 [39] | South Korea | 82 | 82/0 | 28 (22–53) y M(range) | 51,5 (0,25-276) m M(range) | Cross-sectional | 100 | 2009-2010 | 97 | 2 U | PPD-RT23 | 100 |
Moon et al., 2011 [44] | South Korea | 173 | 102/71 | 32 (22–67) y M(range) | 7 (0,2-42) y M(range) | Cross-sectional | 100 | 2010 | 98 | 2 U | PPD-RT23 | 100 |
Jung et al., 2012 [48] | South Korea | 153 | 48/105 | 21.9 ± 0.9 y m + SD | / | Cross-sectional | 108 | 2010-2012 | 102 | 2 U | PPD-RT23 | 86 |
Jo et al., 2013 [50] | South Korea | 493 | 383/110 | 30,6 ± 6,0 y m + SD | <1 y 8,3% 1–5 y 49,7% 6–10 y 23,1% 11–15 y 13,8% ≥ 15 y 5,1% | Cross-sectional | 100 | 2012 | 108 | 2 U | PPD-RT23 | 81 |
Whitaker et al., 2013 [51] | Georgia | 319 | 259/60 | 18-29 y 20% 30–39 y 26% 40–49 y 31% ≥ 50 y 23% | 0-4 y 22% 5–14 y 26% 15–24 y 23% ≥ 25 y 29% | Prospective | 125 | 2009-2011 | 128 | 5 U | PPD-S | 90 |
Mirtskhulava et al., 2008 [27] | Georgia | 265 | 229/36 | 42 (18–74) y m(range) | 8 (1–42) y M (range) | Cross-sectional | 125 | 2006 | 160 | 5 U | PPD-S | 78 |
Lien et al., 2009 [37] | Vietnam | 265 | 197/68 | 40 (20–58) y M(range) | <2 y 11% ≥2 < 5 y 17,7% ≥5 < 10 y 16,6% ≥10 y 54,7% | Cross-sectional | 151 | 2007 | 202 | 5 U | PPD (Pasteur Institute, Vietnam) | 33 |
Pai et al., 2008 [28] | India | 719 | 446/273 | 22 y M | / | Cohort | 249 | 2004 | 212 | 1 U | PPD-RT23 | 71 |
He et al., 2012 [49] | Mongolia | 917 | 659/258 | 18-29 y 22% 30–39 y 23% 40–49 y 35% ≥ 50 y 20% | 10 (<1-50) y M(range) | Cross-sectional | 223 | 2010 | 224 | 5 U | missing data | 34 |